Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups

Executive Summary

REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.

You may also be interested in...



Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria

Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.

Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture

Private Company Edition: Westlake Village BioPartners launched with $320m and Harper as a managing director; UK-based Ahren unveiled a $100m-plus "deep science" fund; and UCSD partnered with Deerfield to finance drug programs. In new financings, Allogene leads with $120m.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC100478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel